Aligos Therapeutics extends South San Francisco headquarters lease to 2034

Aligos Therapeutics disclosed in an 8-K filing that on September 10, 2026, it entered into the First Amendment to Lease with Britannia Biotech Gateway Limited Partnership, amending a lease originally dated June 21, 2018, covering office space at One Corporate Drive, 2nd Floor, South San Francisco, CA, which serves as the company's headquarters.¹ The amendment extends the lease term from March 31, 2027 to March 31, 2034.¹

Under the new terms, base monthly rent per rentable square foot will step up over the extended term, starting at $4.650 from April 1, 2027 to March 31, 2028 and rising annually to $5.716 from April 1, 2033 to March 31, 2034, with the company also responsible for a specified percentage of certain landlord expenses.¹ Aligos will also receive a ten-month rent abatement from April 1, 2027 to January 31, 2028, contingent on no material default under the lease.¹

The amendment includes two early exit provisions. Aligos has a one-time option to terminate the lease as of March 31, 2031 by giving written notice on or before March 31, 2030 and paying $2,476,429.22 in termination consideration, and it also has the right to terminate without penalty on 30 days' notice if it and the landlord or an affiliate execute a new lease for other space in the same project or another project owned by the landlord or an affiliate, covering at least 60,000 rentable square feet and extending beyond the amended lease's expiration.¹

The filing also notes a change to a renewal option: the existing extension option was revised from a single eight-year option to a single seven-year option, exercisable by written notice for the seven-year period following expiration of the extended term.¹

The full text of the First Amendment will be filed as an exhibit to Aligos's Form 10-Q for the fiscal quarter ending September 30, 2026.¹ The 8-K was signed September 15, 2026 by Lesley Ann Calhoun, the company's Executive Vice President, Chief Operating Officer and Chief Financial Officer.